Natera, Inc. announced significant updates by the National Comprehensive Cancer Network (NCCN) to its Clinical Practice Guidelines in Oncology. These updates strengthen the guidance on circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing for colon cancer, rectal cancer, and Merkel cell carcinoma (MCC).
For colon and rectal cancer, NCCN now includes ctDNA as a high-risk factor for recurrence in the adjuvant setting, formally recognizing its prognostic value. This represents a major step forward in integrating ctDNA into standard clinical practice.
In Merkel Cell Carcinoma, the updated NCCN guidelines now include a positive recommendation for ctDNA monitoring in surveillance, citing specific Signatera data. This is particularly impactful for MCC, a rare skin cancer with a 40% recurrence rate within five years, and sets a precedent for ctDNA testing across other indications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.